Advances in Complement Inhibitory Strategies for the Treatment of Glomerular Disease: A Rapidly Evolving Field

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Growing evidence implicates the complement system in diverse kidney diseases beyond atypical hemolytic uremic syndrome (aHUS) and C3 glomerulopathy (C3G).
• Conditions like ANCA-associated vasculitis, immune-complex glomerulonephritis, membranous nephropathy, and IgA nephropathy (IgAN) increasingly show complement involvement.
• The development of targeted complement inhibitors has rapidly advanced, offering new therapeutic avenues.

Purpose of the Study:

• To provide practical guidance for nephrologists on navigating emerging complement-targeting therapies.
• To focus on the clinical application of these agents in specific kidney diseases.
• To address challenges in the real-world implementation of complement inhibitors.

Main Methods:

• Review of current scientific evidence on complement's role in kidney disease.
• Analysis of recently approved and investigational complement-targeting agents.
• Presentation of clinical vignettes to illustrate therapeutic strategies for aHUS, C3G, and IgAN.

Main Results:

• Therapeutic agents targeting complement pathways are now approved for ANCA-associated vasculitis, IgA nephropathy (IgAN), and C3 glomerulopathy (C3G).
• These approvals signify a paradigm shift in managing complement-mediated kidney diseases.
• Clinical implementation requires careful consideration of patient selection and treatment protocols.

Conclusions:

• The complement system is a critical therapeutic target in a growing spectrum of kidney diseases.
• Nephrologists need practical guidance to effectively utilize new complement inhibitors.
• This review aims to bridge the gap between therapeutic innovation and clinical practice for aHUS, C3G, and IgAN.